4//SEC Filing
Protea Biosciences Group, Inc. 4
Accession 0001140361-16-055706
CIK 0001335103operating
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 12:44 PM ET
Size
16.1 KB
Accession
0001140361-16-055706
Insider Transaction Report
Form 4
ANTOLINE STEVE
Director10% Owner
Transactions
- Other
Common Stock
2015-10-12+244,456→ 6,053,853 total(indirect: By Summit Resources, Inc.) - Other
Common Stock
2016-02-03+165,573→ 6,319,426 total(indirect: By Summit Resources, Inc.) - Award
Common Stock
2015-12-18+100,000→ 6,153,853 total(indirect: By Summit Resources, Inc.) - Other
Common Stock
2015-04-14+363,273→ 5,615,503 total(indirect: By Summit Resources, Inc.) - Other
Common Stock
2015-06-30+193,894→ 5,809,397 total(indirect: By Summit Resources, Inc.) - Award
Director Stock Option (right to buy)
2015-12-18+66,667→ 66,667 totalExercise: $0.25From: 2016-12-01Exp: 2025-12-01→ Common Stock (66,667 underlying)
Holdings
- 1,514,048(indirect: By Trust)
Common Stock
Footnotes (7)
- [F1]The Issuer issued 363,273 shares of its Common Stock to Summit Resources, Inc. ("Summit") pursuant to the anti-dilution provisions in those certain Subscription Agreements and Unit Purchase Agreements dated November 1, 2013 and December 30, 2013 entered into by Summit and the Issuer.
- [F2]Steve Antoline (the "Reporting Person") is the president of Summit and has sole voting and dispositive control over the securities held thereby.
- [F3]The Issuer issued 193,894 shares of its Common Stock to Summit pursuant to the anti-dilution provisions in those certain Subscription Agreements and Unit Purchase Agreements dated November 1, 2013 and December 30, 2013 entered into by Summit and the Issuer.
- [F4]On October 12, 2015, the Issuer's Board of Directors authorized the conversion of an aggregate of $49,999.98 of accrued interest on promissory notes issued by the Issuer to Summit, and $11,114.06 of accounts payable by the Issuer to Summit, into shares of Common Stock at a rate of $0.25 per share, resulting in the issuance of 244,456 shares of Common Stock to Summit.
- [F5]On February 3, 2016, the Issuer's Board of Directors authorized the conversion of an aggregate of $33,333.33 of accrued interest on promissory notes issued by the Issuer to Summit, and $8,060.00 of accounts payable by the Issuer to Summit, into shares of Common Stock at a rate of $0.25 per share, resulting in the issuance of 165,573 shares of Common Stock to Summit.
- [F6]The Reporting Person is the trustee of the Steven A. Antoline 2006 Irrevocable Trust and has sole voting and dispositive control over the securities held thereby.
- [F7]The option vests 100% on December 1, 2016.
Documents
Issuer
Protea Biosciences Group, Inc.
CIK 0001335103
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001335103
Filing Metadata
- Form type
- 4
- Filed
- Feb 29, 7:00 PM ET
- Accepted
- Mar 1, 12:44 PM ET
- Size
- 16.1 KB